- Email: [email protected]
S8. Evaluation of quality of life of patients with oral cancer in Brazil
doi:10.1016/j.oos.2009.06.048
University of Michigan, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.044
S4. The future of reconstructive surgery of the head and neck T. Teknos The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, USA [Abstract not available at time of print.]
PD32. Secondary soft tissue defects T. Teknos doi:10.1016/j.oos.2009.06.049 The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, USA [Abstract not available at time of print.]
Symposium: Brazilian society of head and neck surgery
doi:10.1016/j.oos.2009.06.045
S5. Clinical and epidemilogical features of oral cancer in Brazil: Predominance of advanced disease M.D. Durazzo
Symposium: American Head and Neck Society (AHNS)
TBC, Brazil
S1. Molecular detection strategies in OSCC P. Ha The Johns Hopkins School of Medicine, USA The Milton J. Dance Head and Neck Center, USA The Greater Baltimore Medical Center, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.046
[Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.050
S6. Prognosis in early stage oral squamous cell carcinoma F.L. Diaz TBC, Brazil [Abstract not available at time of print.]
S2. Leukoplakia revisited S. Silverman
doi:10.1016/j.oos.2009.06.051
University of California, USA Leukoplakia is the clinical manifestation of hyperkeratosis, presenting as a mucosal white patch that cannot be wiped off. While the mechanism of carcinogenesis associated with hyperkeratosis remains unknown, there is always a risk of transformation. Therefore, leukoplakia must be classified to determine all clinical and biologic risk factors. This presentation will cover epidemiology, clinical characteristics, risk factors, diagnosis, the significance of microscopic dysplasia, and management. Diagnosis is established by incisional biopsy. Adjunctive diagnostic techniques (brush biopsy, toluidine blue, vizilite) will be mentioned, as will the search for biologic markers, e.g. ploidy, loss of heterozygosity. The status of retinoid chemoprevention will be cited. Management entails removing irritants, including tobacco and alcohol, careful microscopic evaluation, and surgical removal. The use of laser will be illustrated.
S7. Survival in advanced oral cancer L.P. Kowalski Hospital AC Camargo, Brazil [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.052
S8. Evaluation of quality of life of patients with oral cancer in Brazil J.G. Vartanian Head and Neck Surgery Department, AC Camargo Hospital, Brazil
doi:10.1016/j.oos.2009.06.047
S3. Surgical extirpation of oral cancers S. Wang University of California, USA [Abstract not available at time of print.]
Oral cavity cancer and its treatment could lead to several degrees of physical, functional, emotional as well as social disabilities, with a potential negative impact on the patient’s quality of life. Most oral cancer patients in Brazil are diagnosed at advanced stages, which usually result in a worse oncological and quality of life outcomes. However, in some series of Brazilian survived oral cancer patients, most of them reported a good and acceptable quality of life. Cultural and social factors could be responsible for such results.
Poster Abstracts Oral AbstractsPoster List
PD31. Biphosphonate necrosis J. Helman
17
Pan. Disc. & Symp. Abs.Keynote Abs.Keynote Bios.ProgramIAOOWelcomeCommittee Listings
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
Pan. Disc. & Symp. Abs.Keynote Abs.Keynote Bios.ProgramIAOOWelcomeCommittee Listings Poster Abstracts Oral AbstractsPoster List
18
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
In a recent Brazilian series of patients submitted to major surgical procedures, they reported that they would not like to exchange their present outcome for another treatment option with a lower chance of cure but with a possibly improved quality of life. Such finding highlighted the importance of disease control with aggressive approaches, and the effectiveness of rehabilitation programs in surgically treated patients in the era of organ-preserving therapies. doi:10.1016/j.oos.2009.06.053
Symposium: American Society of Radiation Oncology (ASTRO) S9. Radiotherapy innovation in the management of loco-regional recurrence of head and neck cancer L. Harrison TBC, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.054
S10. The emerging role of biomarker profiling and functional imaging for guidance of head and neck cancer management S.V. Porceddu Princess Alexandra Hospital, Brisbane, Australia University of Queensland, Brisbane, Australia The current focus is to identify methods and patients to tailor or de-escalate treatment intensity to reduce toxicity with minimal, no loss or improvement in control rates. Biomarkers and functional imaging with positron emission tomography (PET) are emerging as potential tools to achieve this goal. A number of biomarkers associated with outcomes in head and neck cancer (HNC) have been identified, but their role in modifying treatment are yet to be fully defined. Currently, the presence of HPVpositive oropharyngeal squamous cell carcinoma is the strongest biomarker, predicting for favourable outcomes. Treatment de-escalation is attractive in this group. Trials to address this question are being considered with epidermal growth factor receptor antibodies, as possible candidates for less intense treatments. Functional imaging with fluorodeoxyglucose (FDG) PET has emerged as a valuable oncologic tool. Re-staging with FDG PET has a high negative predictive value for the detection of residual nodal disease in HNC following RT and can now be used to guide the subsequent management of the neck. In addition to anatomic delineation, PET has the ability to qualitatively describe tumors. Radio-isotopes such as FAZA, F-Miso and FLT in combination with PET, has the potential to biologically characterise tumors, pre-, during and post-therapy and tailor treatment accordingly. Biomarkers and functional imaging to characterise tumors at a molecular level are being explored to modify treatment and improve the therapeutic ratio. doi:10.1016/j.oos.2009.06.055
Recent innovations in advanced radiation planning, treatment delivery and accuracy verification technologies have changed the clinical practice of head and neck radiation oncology and research landscape. Highly conformal radiation therapy, such as intensitymodulated radiation therapy (IMRT), enables the delivery of radiation to complex 3-dimensional target volumes while limiting radiation dose to nearby critical normal tissues. There is an emerging body of evidence demonstrating the clinical benefits of IMRT. A prerequisite of head and neck IMRT planning is the detailed volumetric delineation (contouring) of radiation targets and normal tissues. Contouring requires a more rigorous application of knowledge of radiologic and surgical anatomy, tumour localization, and disease patterns compared to the 2-dimensional era. The contouring process can be very time consuming. Novel autosegmentation (automatic contouring) tools enable radiation oncologists to delineate complex structures accurately but more efficiently. While not widely available clinically, sophisticated 3-dimensional tools are in development. Conformal radiotherapy requires assessments of the accuracy of treatment delivery. These assessments can be made during a course of radiotherapy with state-of-the art image-guided radiation therapy (IGRT) technologies. Corrective strategies for patient set-up displacements and organ motion/target variability can be implemented during a course of radiotherapy. IGRT offers the potential to further limit dose to normal tissues by enabling the safe reduction of normal tissue margins currently incorporated in radiation therapy planning. IGRT also offers the potential to adapt radiation therapy to patient and tumour changes during a course a radiotherapy. Advanced technologies facilitate the clinical exploitation of radiobiologic principles to control tumour and limit toxicity. doi:10.1016/j.oos.2009.06.056
Symposium: European Head and Neck Society (EHNS) S12. Non surgical approaches J. Bourhis TBC, France [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.057
S13. Robotic surgery M. van der Breckel Netherlands Cancer Institute, The Netherlands [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.058
S14. HPV J. Klozar Motol Faculty Hospital, Czech Republic
S11. Automation, adaptation and advanced image guidance in head and neck radiation therapy J.J. Kim Princess Margaret Hospital, University of Toronto, Canada
[Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.059
University of Michigan, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.044
S4. The future of reconstructive surgery of the head and neck T. Teknos The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, USA [Abstract not available at time of print.]
PD32. Secondary soft tissue defects T. Teknos doi:10.1016/j.oos.2009.06.049 The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, USA [Abstract not available at time of print.]
Symposium: Brazilian society of head and neck surgery
doi:10.1016/j.oos.2009.06.045
S5. Clinical and epidemilogical features of oral cancer in Brazil: Predominance of advanced disease M.D. Durazzo
Symposium: American Head and Neck Society (AHNS)
TBC, Brazil
S1. Molecular detection strategies in OSCC P. Ha The Johns Hopkins School of Medicine, USA The Milton J. Dance Head and Neck Center, USA The Greater Baltimore Medical Center, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.046
[Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.050
S6. Prognosis in early stage oral squamous cell carcinoma F.L. Diaz TBC, Brazil [Abstract not available at time of print.]
S2. Leukoplakia revisited S. Silverman
doi:10.1016/j.oos.2009.06.051
University of California, USA Leukoplakia is the clinical manifestation of hyperkeratosis, presenting as a mucosal white patch that cannot be wiped off. While the mechanism of carcinogenesis associated with hyperkeratosis remains unknown, there is always a risk of transformation. Therefore, leukoplakia must be classified to determine all clinical and biologic risk factors. This presentation will cover epidemiology, clinical characteristics, risk factors, diagnosis, the significance of microscopic dysplasia, and management. Diagnosis is established by incisional biopsy. Adjunctive diagnostic techniques (brush biopsy, toluidine blue, vizilite) will be mentioned, as will the search for biologic markers, e.g. ploidy, loss of heterozygosity. The status of retinoid chemoprevention will be cited. Management entails removing irritants, including tobacco and alcohol, careful microscopic evaluation, and surgical removal. The use of laser will be illustrated.
S7. Survival in advanced oral cancer L.P. Kowalski Hospital AC Camargo, Brazil [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.052
S8. Evaluation of quality of life of patients with oral cancer in Brazil J.G. Vartanian Head and Neck Surgery Department, AC Camargo Hospital, Brazil
doi:10.1016/j.oos.2009.06.047
S3. Surgical extirpation of oral cancers S. Wang University of California, USA [Abstract not available at time of print.]
Oral cavity cancer and its treatment could lead to several degrees of physical, functional, emotional as well as social disabilities, with a potential negative impact on the patient’s quality of life. Most oral cancer patients in Brazil are diagnosed at advanced stages, which usually result in a worse oncological and quality of life outcomes. However, in some series of Brazilian survived oral cancer patients, most of them reported a good and acceptable quality of life. Cultural and social factors could be responsible for such results.
Poster Abstracts Oral AbstractsPoster List
PD31. Biphosphonate necrosis J. Helman
17
Pan. Disc. & Symp. Abs.Keynote Abs.Keynote Bios.ProgramIAOOWelcomeCommittee Listings
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
Pan. Disc. & Symp. Abs.Keynote Abs.Keynote Bios.ProgramIAOOWelcomeCommittee Listings Poster Abstracts Oral AbstractsPoster List
18
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
In a recent Brazilian series of patients submitted to major surgical procedures, they reported that they would not like to exchange their present outcome for another treatment option with a lower chance of cure but with a possibly improved quality of life. Such finding highlighted the importance of disease control with aggressive approaches, and the effectiveness of rehabilitation programs in surgically treated patients in the era of organ-preserving therapies. doi:10.1016/j.oos.2009.06.053
Symposium: American Society of Radiation Oncology (ASTRO) S9. Radiotherapy innovation in the management of loco-regional recurrence of head and neck cancer L. Harrison TBC, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.054
S10. The emerging role of biomarker profiling and functional imaging for guidance of head and neck cancer management S.V. Porceddu Princess Alexandra Hospital, Brisbane, Australia University of Queensland, Brisbane, Australia The current focus is to identify methods and patients to tailor or de-escalate treatment intensity to reduce toxicity with minimal, no loss or improvement in control rates. Biomarkers and functional imaging with positron emission tomography (PET) are emerging as potential tools to achieve this goal. A number of biomarkers associated with outcomes in head and neck cancer (HNC) have been identified, but their role in modifying treatment are yet to be fully defined. Currently, the presence of HPVpositive oropharyngeal squamous cell carcinoma is the strongest biomarker, predicting for favourable outcomes. Treatment de-escalation is attractive in this group. Trials to address this question are being considered with epidermal growth factor receptor antibodies, as possible candidates for less intense treatments. Functional imaging with fluorodeoxyglucose (FDG) PET has emerged as a valuable oncologic tool. Re-staging with FDG PET has a high negative predictive value for the detection of residual nodal disease in HNC following RT and can now be used to guide the subsequent management of the neck. In addition to anatomic delineation, PET has the ability to qualitatively describe tumors. Radio-isotopes such as FAZA, F-Miso and FLT in combination with PET, has the potential to biologically characterise tumors, pre-, during and post-therapy and tailor treatment accordingly. Biomarkers and functional imaging to characterise tumors at a molecular level are being explored to modify treatment and improve the therapeutic ratio. doi:10.1016/j.oos.2009.06.055
Recent innovations in advanced radiation planning, treatment delivery and accuracy verification technologies have changed the clinical practice of head and neck radiation oncology and research landscape. Highly conformal radiation therapy, such as intensitymodulated radiation therapy (IMRT), enables the delivery of radiation to complex 3-dimensional target volumes while limiting radiation dose to nearby critical normal tissues. There is an emerging body of evidence demonstrating the clinical benefits of IMRT. A prerequisite of head and neck IMRT planning is the detailed volumetric delineation (contouring) of radiation targets and normal tissues. Contouring requires a more rigorous application of knowledge of radiologic and surgical anatomy, tumour localization, and disease patterns compared to the 2-dimensional era. The contouring process can be very time consuming. Novel autosegmentation (automatic contouring) tools enable radiation oncologists to delineate complex structures accurately but more efficiently. While not widely available clinically, sophisticated 3-dimensional tools are in development. Conformal radiotherapy requires assessments of the accuracy of treatment delivery. These assessments can be made during a course of radiotherapy with state-of-the art image-guided radiation therapy (IGRT) technologies. Corrective strategies for patient set-up displacements and organ motion/target variability can be implemented during a course of radiotherapy. IGRT offers the potential to further limit dose to normal tissues by enabling the safe reduction of normal tissue margins currently incorporated in radiation therapy planning. IGRT also offers the potential to adapt radiation therapy to patient and tumour changes during a course a radiotherapy. Advanced technologies facilitate the clinical exploitation of radiobiologic principles to control tumour and limit toxicity. doi:10.1016/j.oos.2009.06.056
Symposium: European Head and Neck Society (EHNS) S12. Non surgical approaches J. Bourhis TBC, France [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.057
S13. Robotic surgery M. van der Breckel Netherlands Cancer Institute, The Netherlands [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.058
S14. HPV J. Klozar Motol Faculty Hospital, Czech Republic
S11. Automation, adaptation and advanced image guidance in head and neck radiation therapy J.J. Kim Princess Margaret Hospital, University of Toronto, Canada
[Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.059